Treatment of congenital immune deficiencies with a thymic hormone--thymic humoral factor.
Five infants with congenital immune defects are presented. Three had various combined immune deficiencies (CID) and two had thymic deficiencies only. As bone marrow or thymus transplantations were not feasible in these patients, we attempted treatment with thymic humoral factor (THF), a thymic hormone, by daily i.m. injections during biweekly courses. In one CID patient, a partial improvement in immune indices and temporary clinical improvement were achieved. In the other two, THF did not arrest the patients' demise. The two patients with thymic dysplasia benefitted repeatedly from THF treatment, as exemplified by the disappearance of wasting, diarrhea and infections and by reconstitution of T cell parameters. Nevertheless, the patients relapsed after prolonged periods without THF administration. We therefore propose the administration of long-term, continuous or intermittent thymic hormone replacement therapy in infants with congenital thymic defects. Early diagnosis and immediate institution of treatment will probably improve prognosis.
D005260:Female; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000151:congenital / Q000175:diagnosis / Q000188:drug therapy*; D007158:Immunologic Techniques; D007223:Infant; D008231:Lymphopenia / Q000276:immunology; D008297:Male; D012008:Recurrence; D013950:Thymus Gland / Q000002:abnormalities; D013951:Thymus Hormones / Q000627:therapeutic use*
D013951:Thymus Hormones; C014859:thymic humoral factor